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Adult zebrafishIntroduction: Mycobacteriummarinum has emerged as a suitable species for induction of tuber-
culosis-like disease in zebrafish, and various zebrafish models (larval and adult) for drug
screening have been proposed in the literature. It is believed that an adult zebrafish model
is more useful in drug screening because, apart from assessment of efficacy, one can obtain
data on dosage, pharmacokinetics and overall health improvement. This study suggests a
simple, cost-effectiveand resource-efficientprotocol for screeningof anti-tuberculosis drugs.
Methods: The parameters used for assessment of infection aswell as anti-bacterial response
were: (a) bacterial count; and (b) bodyweight change.Anoptimization studywas conducted to
establish theconcentrationofbacteria required toproducea reproduciblephenotypeof tuber-
culosis (TB). A negative control (Amoxicillin) and anti-mycobacterial drugs (Isoniazid, Rifam-
picin, Moxifloxacin, Ethambutol and Isoniazid + Rifampicin) were used for validation of the
protocol. All the drugs were administered orally.
Results: An intra-peritoneal inoculation of 0.75 million bacteria/fish was optimized for the
model. All the anti-tuberculosis drugs showed efficacy in this model, whereas the negative
control did not show any signs of reversing the parameters ofM. marinum infection.
Discussion: Adult zebrafish model of M. marinum-induced tuberculosis has not been fully
exploited as a drug screening tool. In thepresent report, a protocol is suggested that is simple,
reproducible and resource-efficient for screening of anti-tuberculosis agents. This protocol is
an attempt to refine the published protocols and use this model as a surrogate model of
human TB for the purpose of drug screening.
 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction oping and underdeveloped countries across the world. ManyHuman tuberculosis (TB), caused by Myocbacterium tubercu-
losis, is one of the major health challenges faced by the devel-academic as well as industrial researchers are engaged in
understanding this disease, as well as finding a therapeutic
cure for this disease using animal experimentation. The mostad 500046,
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pig and rabbit models, have limitations in terms of represen-
tation of the disease process in human TB [1,2]. Nonhuman
primates are considered to be the most predictive models to
mimic human TB [3], but their use has been limited because
of cost and ethical issues. Therefore, there is a need to have
alternate models for the study of TB, as well as to screen
potential anti-TB agents during drug discovery.
Mycobacterium marinum is a marine counterpart ofM. tuber-
culosis [4] and performs all essential functions required to eli-
cit a granulomatous disease [5,6]. It grows optimally at
temperatures between 33 C and 35 C and can thus produce
TB in ectotherms–zebrafish being the most popular amongst
them. Furthermore, the innate and adaptive immune system
of zebrafish is similar to that of the human system [7].M. mar-
inum can be safely handled using BSL-II precautions, because
its infection in humans is quite localized and does not impact
the user systemically unless the host is severely immune-
compromised [8].
This current study is based on the previous literature, to
use zebrafish as a surrogate model for drug screening, as a
step between in vitro assessment and in vivo pharmacological
evaluation in mammalian models. A simple adult zebrafish
model was standardized to screen compounds using a proto-
col that is resource efficient, inexpensive, involves simple
techniques and does not require sophisticated instrumenta-
tion. This protocol is based on parameters of: (a) bacterial
count, and (b) body weight change. Furthermore, oral drug
administration was employed to ensure the systemic delivery
of drugs and ascertain the dose of the drugs administered to
each fish. The protocol has been validated using standard
drugs wherein isoniazid, rifampicin, moxifloxacin, ethambu-
tol and isoniazid + rifampicin (combination) were used as
positive controls, whereas, amoxicillin was used as a negative
control.Animal ethics statement
Experiments were performed following animal ethics guide-
lines of the institutions and were performed under the super-
vision of a licensed veterinarian. The mortality rate due to
infection in adult zebrafish was similar to that observed in
other mammalian models of TB [see Results Section 4.1].Methods
Zebrafish maintenance
Zebrafish were maintained as per Guidelines for Use of Zebra-
fish in the NIH Intramural Research Program [9] and the Zeb-
rafish Book [10]. Zebrafish were obtained from Vikrant
Aquaculture, Mumbai, India, and were maintained at BITS-
Pilani, Hyderabad campus, India as per the procedures men-
tioned earlier [11,12]. Briefly, all the fish were taken care to
acclimatize for a week at 26–28 C and at conditions of
14:10 hr. (light:dark) every day. The fish were allowed to swim
in separate chambers filled with filtered water containing
0.2% sea salt and were fed with dry food (procured from thesame vendor) at three regular intervals daily. Fish were
observed to be healthy through their feeding and swimming
activities and with a weight range of 500 mg. The healthy fish
were further selected to conduct the study.
M. marinum strains, culture condition and inoculation
M. marinum strains used for this study were derived from a
human clinical isolate, strain M (ATCC BAA-535), and were
grown at 30 C in Middlebrook 7H9 broth (HiMedia)
supplemented with Middlebrook OADC Growth supplement
(HiMedia) and 0.05% Tween 80 or on Middlebrook 7H10agar
(HiMedia) supplemented with Middlebrook OADC Growth
supplement (HiMedia). Infected fish homogenates were pla-
ted in 48 well plates using Middlebrook 7H9 broth (HiMedia)
supplemented with amphotericin B (10 mg/liter) and poly-
myxin B (20 mg/liter), to avoid contamination with normal
flora. Cultures used in infections were grown to an optical
density at 600 nm of 1.0 and maintained at 80 C in 1-ml ali-
quots with 10% glycerol [2]. Intraperitoneal administration
(i.p.) was used for bacterial inoculation, wherein a maximum
volume of 15 ll/fish was injected using a 29-gauge insulin syr-
inge to avoid injury-induced stress based on methods
described in the literature [12,13].
Drug, vehicle and drug administration
The standard drugs Isoniazid, Rifampicin, Ethambutol, Moxi-
floxacin, and Amoxicillin were procured from Sigma Aldrich,
and Tween 80 was procured from NICE laboratories. All other
routine chemicals were procured locally. All drugs were
administered orally using a recently reported method
[11,14]. This method allows the calculation of the oral dose
of the drugs in terms of milligrams per kilograms (mg/kg),
which is very useful in ascertaining the vital parameter of
drug dosage required for ranking of molecules and taking
decisions in a screening program. The authors that proposed
this method have demonstrated the credibility of the method
by substantiated pharmacokinetics and pharmacology data.
Optimization study
A study was conducted to optimize the concentration of bac-
teria needed to produce a reproducible phenotype of zebrafish
TB. Healthy fish were grouped into four groups (n = 15/group)
and M. marinum cultures were injected into the fish (inside a
BSL-II hood) at inoculums of 0.5 (Group I), 0.6 (Group II) and
0.75 (Group III) million bacteria respectively. Two time points
viz. day 7 and 14 were used to sacrifice the fish and results
were determined using Most Probable Number (MPN) assay
(n = 6) and body weight (n = 10). Before sacrificing, the fish
were allowed to swim in 1.5 mg/ml of Kanamycin Sulfate
for 45 min at 27 C, to prevent any cross-infection [2].
Thereafter, the fish were homogenized and processed for
MPN assay as per a published protocol [15]. MPN values were
finally calculated using standard statistical methods [16]. The
survival probability curve of Group III fish was also plotted by
conducting a separate experiment on 90 fish based on Kap-
lan–Meier survival analysis [17].
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An in vivo protocol using the standard drugs was further
designed. It was performed as a two-week study: infection
stage (0–7th day) and treatment stage (8th–14th day). Eighty
fish were inoculated with an optimized count of M. marinum.
A dose optimization study resulted in finalizing the following
drug doses: amoxicillin (10 mg/kg), isoniazid (10 mg/kg), rif-
ampicin (5 mg/kg), moxifloxacin (5 mg/kg), ethambutol
(10 mg/kg) and a combination of isoniazid (5 mg/kg) + rifam-
picin (2.5 mg/kg). The drug solutions (diluted with vehicle
Tween 80) were prepared considering the average body
weights of the fish in each group. 5 ll of each drug (n = 10 in
each group) was administered orally. This dosing was done
for a week (8th–14th day), and the results were determined
using MPN assay (n = 6) and body weight (n = 10).
Results
Optimization study
The lesions observed in infected fish were redness with squa-
mous eruptions (in the form of white fibers) (Fig. 1).
The MPN assay showed a clear dose response in the
increase of the bacterial counts (Fig. 2). Group I showed
approximately 1.2- and 1.8-fold increase in MPN on days 7
and 14 respectively. Group II showed an increase of 1.5- and
3.1-fold increase in bacterial counts on the days of sacrifice
(days 7 and 14). The highest increase was seen in Group III
with an increase of 4.1 on day 7 post infections and a huge
12.8-fold increase on day 14 post infection.
Body weight reduction was seen in a dose response man-
ner (Fig. 3). The mean body weight reduction in the control
group was 1.7 ± 2% and 0 ± 1.8% on days 8 and 14 post infec-
tion, respectively. Whereas, in the infected groups, the reduc-
tion was significantly higher within 8 days post infection and
was observed to be 18.5 ± 1.5%, 29.5 ± 1.8% and 31.7 ± 1.4% in
Groups I, II and III, respectively. On day 14, there was a further
reduction in body weights in all three groups by 22.3 ± 1.6%,
33.2 ± 1.8% and 41.2 ± 1.1% in Groups I, II and III, respectively.Fig. 1 – M. marinum-induced adult zebrafish with red lesions &
during the study.In order to ensure that Group III was suitable for conduct
of screening experiments, a survival probability assessment
(Fig. 4) was conducted on 90 fish after inoculation of 0.75 mil-
lion bacteria and observation for 14 days for survival. At the
end of 14 days, a survival probability of 0.71 suggested this
dose to be robust and suitable for conducting screening exper-
iments with a substantial sample size surviving for measur-
ing the response of test drugs. It is reported that almost half
(47%) of the experiments conducted on murine models of
TB are based on the criterion of lethality [18], and the biolog-
ical significance for efficacy in such models is generally con-
sidered to be a 20% improvement in survival. Therefore, the
survival probability of >0.7 in this model ought to be suffi-
ciently ‘‘humane’’ for the purpose of drug efficacy evaluation.
Therefore, Group III was the group that showed substantial
symptoms and a high lesion score, >10-fold increase in MPN,
>40% reduction in body weight, and >0.7 survivability. Thus,
an intra-peritoneal inoculation of 0.75 million bacteria/fish
was selected as the suitable paradigm for M. marinum infec-
tion model in adult zebrafish.
Validation study
The dose optimization study helped in selecting the doses for
the final study. Based on the visual observations the dose
groups selected for the final study were: Amoxicillin (10 mg/
kg), Isoniazid (10 mg/kg), Rifampicin (5 mg/kg), Moxifloxacin
(5 mg/kg), Ethambutol (10 mg/kg) and a combination of Isoni-
azid (5 mg/kg) + Rifampicin (2.5 mg/kg).
All the parameters, i.e., MPN assay results (Fig. 5) and body
weight reduction observations (Fig. 6b) demonstrated that the
anti-tuberculosis drugs were efficacious in this model
whereas the negative control Amoxicillin did not show any
signs of efficacy in reversing the parameters of M. marinum
infection.
The average bacterial counts were >12-fold higher in the
infected group and the data was consistent with the results
seen in the optimization study. The Amoxicillin treated group
also showed MPN equivalent to the infection control fish.
Fish treated with all the drugs showed almost completesquamous eruptions on dorsal and lateral sides observed
Fig. 3 – Percentage body weight reduction observed in groups control-uninfected, I, II, III (Mean ± S.E.M., n = 10) on days 7 and
14 during the bacterial optimization study of M. marinum-induced adult zebrafish model. The statistical significance
(*p < 0.05, **p < 0.01 and ***p < 0.001) with respect to un-infected control group has been analyzed by one-way ANOVA using
GraphPad Prism Software.
Fig. 2 – Bacterial counts of groups I, II, III (Mean ± S.E.M., n = 6) on days 7 and 14 during the optimization study ofM. marinum-
induced adult zebrafish model.
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significance.
The data on body weight reduction showed that fish
treated with Moxifloxacin and the combination of Isoniazid +
Rifampicin did not show any significant reduction in body
weight as compared with the untreated control on day 14 of
the study. Furthermore, there was a reduction in body weights
for the first seven days of the infection phase which improved
in the treatment phase (Fig. 6a). Fish treated with Isoniazid,
Rifampicin and Ethambutol showed a statistically significant
reduction in body weight as compared with the untreatedcontrol; however, the reduction seen in the infected control
group and the Amoxicillin treated group was over 50%, which
showed a severe infection in these fish.
Overall, the evaluation that the anti-tuberculosis could be
ranked for efficacy in the following order is based on various
parameters summarized in Table 1:
(a) Moxifloxacin
(b) Isoniazid + Rifampicin
(c) Rifampicin
(d) Ethambutol
(e) Isoniazid
Fig. 4 – Kaplan–Meier survival analysis performed to know survival probability of Group III fish inducedwith 750,000 bacteria.
Fig. 5 – Bacterial count estimation (Mean ± S.E.M., n = 6) for control and treated groups conducted by using MPN (most
probable number) assay. The statistical significance (*p < 0.05, **p < 0.01 and ***p < 0.001) with respect to infected control group
has been analyzed by one-way ANOVA using GraphPad Prism Software.
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Isoniazid + Rifampicin are more efficacious in human TB fol-
lowed by the other three studies in this experiment. This resultsuggests that the efficacy profile observed in the zebrafish
model is similar to the one seen in a clinical situation, demon-
strating the predictive value of this model in drug screening.
Fig. 6a – Mean body weight changes observed (Mean ± S.E.M., n = 10) with respective days post infection for all the groups
during the study of M. marinum-induced adult zebrafish model.
Fig. 6b – Percentage body weight reduction (Mean ± S.E.M., n = 10) over the study period for control and treated groups of M.
marinum-induced adult zebrafish model. The statistical significance (*p < 0.05, **p < 0.01 and ***p < 0.001) with respect to un-
infected control group has been analyzed by one-way ANOVA using GraphPad Prism Software.
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The use of adult zebrafish as a surrogate model for assessing
drug efficacy in TB research has not been fully exploited by
either academicians or by the industry. Important aspects of
establishment of a screening tool for evaluation of pharmaco-logical activity of drugs include genetics and physiology ratio-
nale, predictivity and reproducibility of protocol. The genetic
and physiological relevance ofM. marinum-induced adult zeb-
rafish models of TB has been well established in the literature
[19]. Various methods and models of M. marinum have been
reported in the literature. A rapid high-throughput platform
Table 1 – Ranking of anti-tuberculosis drugs based on various parameters of efficacy in M. marinum-induced adult zebrafish
model of tuberculosis.
Rank Anti-tuberculosis drug Dose Parameter values (Day 14 post infection)
MPN (million/fish) % Body weight reduction Survivability
1 Moxifloxacin 5 mg/kg 0.01 ± 0.00 4.4 ± 1.0 0.6
2 Isoniazid + Rifampicin 5 mg/kg + 2.5 mg/kg 0.07 ± 0.00 5.3 ± 1.8 0.6
3 Rifampicin 5 mg/kg 0.12 ± 0.01 8.8 ± 1.6 0.7
4 Ethambutol 10 mg/kg 0.14 ± 0.01 10.3 ± 1.6 0.7
5 Isoniazid 10 mg/kg 0.14 ± 0.01 18.7 ± 1.7 0.7
Fig. 7 – Flow chart demonstrating the standardization process followed in developing adult Zebrafish tuberculosis model for
evaluation of oral anti-tuberculosis drugs.
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marinum are monitored using automated plate fluorometry
(APF) has been developed to assess both efficacy and safety
[20]. A similar high-throughput larval model using larval zeb-
rafish has been reported recently [21]. The adult zebrafish
model ofM. marinum infection has been reported [2], however,
the report deals with the study of pathology with respect to
adaptive immunity and this model has not been validated
for drug screening. The present protocol has been inspired
by this report, and an attempt to modify and refine the proto-
col has been made in order to make it reproducible and sim-
ple to conduct.
A flow chart for standardization of the protocol forM. mar-
inum-based adult zebrafish TB model has been suggested in
Fig. 7. It provided for criterion for each step of standardization
and validation of the model. This flow chart will be very use-
ful for the development of such a model in laboratories across
academia and the industry.
It is proposed that the use of adult zebrafish model should
take precedence over the larval model (which has been more
popular) based on the following rationale: adult zebrafish
have optimally developed organs required for drug metabo-
lism [22,23]; poorly soluble drugs may precipitate and will be
unabsorbed in the larval assay and hence cannot be tested
in larval zebrafish; using the oral dosing paradigm, the dosage
of the drugs can be ascertained in terms of mg/kg. Therefore,
even though the larval models can be useful for early high-
throughput screening, the adult model holds greater promise
for the establishment of in vivo proof-of-concept. An alterna-
tive to the oral method of administration, the intraperitoneal
(i.p.) method can also be used for precision drug administra-
tion [24] and for arriving at a dose in terms of mg/kg. The
use of the adult zebrafish model helps us have a fully grown
organism with optimally functioning systems of ADME
(absorption, distribution, metabolism and excretion) and pre-
cise methods for drug administration. This can ensure that
the effect of candidate drugs can be determined to take deci-
sions in preclinical research. This protocol would further help
researchers to correlate drug efficacy data between zebrafish
and other mammalian models.
The methods reported so far using larval zebrafish require
fluorescently labeled organisms and sophisticated visualiza-
tion techniques. Moreover, micro-injections for the inocula-
tion of infection will require specific equipment and trained
manpower. Small academic laboratories and start-up compa-
nies may not be in a position to make these investments for a
small library-based screening program. Even larger organiza-
tions that are not interested in high-throughput screening
would prefer a protocol which can be used in low-resource
settings. This protocol is resource-efficient, inexpensive,
involves simple techniques like bacterial count, body weight
change and survivability.
Literature reports have suggested the use of zebrafish as a
model organism to study various other bacterial infections
like Burkholderia cenocepacia, Pseudomonas aeruginosa, Staphylo-
coccus aureus, Streptococcus pyogenes and Francisella species, the
fungal pathogen Candida albicans and the viral pathogen her-
pes simplex virus type 1 [25–31]. It is believed that these
methods can be modified suitably and applied to these infec-
tions as well.A possible improvement in the present protocol could be
the addition of pharmacokinetic assessment of test drugs in
order to develop pharmacokinetic-pharmacodynamic correla-
tion of efficacy. Drug metabolism can also be assessed in the
same study. In conclusion, the use of adult zebrafish and the
involvement of simple phenotypic parameters ensure obtain-
ing the maximum data about compounds from one study, a
possibility that makes this protocol very useful in drug dis-
covery decision-making.Contributors
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